Lanraplenib.
GS-US-379-1932
Phase 1 small_molecule completed
Quick answer
Lanraplenib. for Inflammatory Disease is a Phase 1 program (small_molecule) at Gilead Sciences Ireland UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences Ireland UC
- Indication
- Inflammatory Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed